EMA Appeals Interim EU Court Orders Preventing Access To Documents
Executive Summary
The European Medicines Agency is looking for a clear indication from the EU courts on whether its approach to transparency – as defined in its access to documents policy – is correct.
You may also be interested in...
Court Decision Means Longer Wait For Clarity On EMA’s Access To Documents Policy
The EU court’s dismissal of appeals filed by the European Medicines Agency in cases relating to its access to documents policy means stakeholders will have to wait even longer to get legal clarity on the policy. One lawyer believes that the case could result in a broader definition of what constitutes commercially confidential information.
EMA Revises Access Policy To Clarify Which Corporate Records Are Public
The European Medicines Agency is inviting feedback on changes to its policy on access to documents to clarify that it also covers the agency’s corporate documents.
It’s Started: EMA Proactively Publishes Clinical Data On New Drugs
The European Medicines Agency has delivered on its promise to grant public access to clinical reports that form the basis of its recommendations to the European Commission on whether or not a medicine should be authorized for use in the EU.